Australia Health

Dimerix (ASX:DXB) announced plans to conduct a blinded assessment of the statistical assumptions underpinning its ongoing ACTION3 study.

Telix Pharmaceuticals (ASX:TLX) has resubmitted its New Drug Application to the US Food and Drug Administration for TLX101-Px.

Australian biotech firm Racura Oncology (ASX:RAC) secured critical governance approval from Monash Health.

Global health-tech innovator Oneview Healthcare (ASX:ONE) secured $19 million through an upsized two-tranche placement.

InteliCare (ASX:ICR) has announced a five-year partnership with leading Victorian not-for-profit aged care provider, MECWA.

Imugene (ASX:IMU) has launched a multi-pronged $20 million capital raising initiative to accelerate its oncological research.

Patrys (ASX:PAB) has commenced key manufacturing and regulatory activities for RLS-2201, a proprietary injectable formulation of Quetiapine.

Rhythm Biosciences (ASX:RHY) achieves its first clinical sale of ColoSTAT, marking its transition to a commercial medical diagnostics company ready for large-scale expansion.

Orthocell (ASX:OCC) has appointed LEDA Orthopaedics as the exclusive distributor for its flagship collagen nerve wrap, Remplir, across the United Kingdom.

Dimerix (ASX:DXB) announced an operational breakthrough in its flagship ACTION3 Phase 3 clinical trial for DMX-200.

Imugene (ASX:IMU) announced exceptional clinical data from the CAR T-naïve cohort of its ongoing Phase 1b basket study of azer-cel.

Clarity Pharmaceuticals (ASX:CU6) has exceeded recruitment targets for its registrational Phase 3 AMPLIFY trial in just nine months.